📰 Alacyclovir News
Page 16 - Alacyclovir News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Alacyclovir. Real-time updates on events, politics, business and more.
November 24, 2021
Transplant patients are particularly vulnerable to cytomegalovirus (CMV) infection, which can lead to organ loss or death.
November 22, 2021
Within weeks, perhaps before many Americans finish decorating for the holidays, the US could have access to a new antiviral pill from Merck expected to alter the deadly trajectory of the pandemic.
November 5, 2021
An experimental antiviral pill appears to work very well at keeping people who are at high risk of severe COVID-19 from being admitted to the hospital and dying, according to the drugs maker, Pfizer.
October 21, 2021
Infectious Diseases Society of America experts provide pandemic recommendations for now and the future, calling for better processes, more inclusive trials, and better review of preprint studies.
October 20, 2021
A World Health Organization-led programme to ensure poorer countries get fair access to COVID-19 vaccines, tests, and treatments aims to secure antiviral drugs for patients with mild symptoms for as little as $10 per course.
October 15, 2021
Data scientists are using a technique known as deep learning, computer algorithms patterned on the brains signaling networks, to identify combinations of medicines to treat infectious disease.
October 11, 2021
Four hundred million people become infected with dengue each year, and 40,000 die, but at present, there is not a single treatment option.
October 11, 2021
"The extraordinary impact of this pandemic demands that we move with unprecedented urgency, and that is what our teams have done by submitting this application for molnupiravir to the FDA..."
October 6, 2021
Promising results from an interim trial of a new pill to treat COVID is causing excitement, but experts still have some questions.
October 1, 2021
Mercks experimental drug molnupiravir reduced the chance of hospitalization or death by around 50% for patients at risk of severe disease, according to interim clinical trial results.